Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab With DA-EPOCH in Newly Diagnosed Plasmablastic Lymphoma
NCT04139304Phase 1Recruiting
- Sponsor
- AIDS Malignancy Consortium
- Start
- May 2021
- Primary completion
- Jul 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in plasmablastic lymphoma (PBL), sponsored by AIDS Malignancy Consortium. Primary endpoint: Percentage of patients completing at least 3 cycles of treatment at 9 weeks. Started May 2021; status: recruiting.
02
Drugs
daratumumab
03
Conditions
plasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on NCT04139304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139304.